Johnson & Johnson: directors' dealings · United States · SEC (Form 4)

About Johnson & Johnson

Johnson & Johnson is a leading U.S. healthcare company listed on the NYSE under the ticker JNJ and headquartered in New Brunswick, New Jersey, United States. Founded in 1887, the company has built one of the most enduring franchises in global healthcare, with operations in virtually all countries and a business model anchored in scale, innovation, and diversification. For French, Belgian, and Swiss investors, JNJ is often viewed as a high-quality defensive large cap, combining pharmaceutical innovation with medical technology exposure and a long record of value creation and dividend growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf)) Johnson & Johnson is now organized into two core operating segments: Innovative Medicine and MedTech. Innovative Medicine covers research, development, manufacturing, and commercialization across major therapeutic areas including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. MedTech brings together a broad portfolio of solutions used in orthopaedics, surgery, cardiovascular care, and vision. This simpler structure gives investors clearer visibility into the group’s strategic priorities and underscores its focus on higher-value healthcare categories. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf)) From a competitive standpoint, JNJ benefits from several structural advantages: a powerful global brand, deep R&D capabilities, a broad clinical and commercial footprint, and a diversified product portfolio spanning both drugs and medical devices. The company competes in highly regulated, innovation-driven markets where intellectual property, clinical execution, and regulatory approvals are critical. Its products and services are sold to hospitals, physicians, distributors, retailers, and healthcare professionals across the United States and international markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000200406/000130817925000085/jnj013333-ars.pdf)) Key franchises include therapies in immunology and oncology, as well as advanced medical devices and surgical technologies. The company continues to emphasize next-generation platforms in oncology, autoimmune disease, and surgical innovation, supporting medium-term growth potential while balancing the maturity of some legacy categories. ([jnj.com](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results)) Recent highlights include the publication of full-year 2025 results, a 2025 quarterly dividend increase, multiple regulatory approvals and product launches, and an October 2025 announcement of intent to separate the Orthopaedics business to sharpen strategic and operational focus. Overall, Johnson & Johnson remains a transformation story within large-cap healthcare, with a resilient balance between cash generation, innovation, and portfolio reshaping. ([jnj.com](https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results))